Sou Hu Cai Jing·2025-10-22 19:26Core Viewpoint - Southbound funds increased their holdings in Fosun Pharma (02196.HK) by 316,500 shares on October 22, 2025, despite experiencing net reductions in holdings on several days in the preceding weeks [1][2]. Group 1: Shareholding Changes - Over the last five trading days, there were two days of net reductions in holdings, totaling a net decrease of 296,000 shares [1]. - In the last twenty trading days, there were twelve days of net reductions, resulting in a cumulative net decrease of 16.5155 million shares [1]. - As of now, southbound funds hold 306 million shares of Fosun Pharma, accounting for 55.51% of the company's total issued ordinary shares [1]. Group 2: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five divisions [2]. - The pharmaceutical division focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics division is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]. - The healthcare services division operates an integrated online and offline medical service platform [2]. - The pharmaceutical distribution and retail division is responsible for the wholesale and retail of pharmaceutical products [2]. - The company's products are mainly used in the treatment of oncology, immunology, and central nervous system disorders [2].